figur address market expans k-toxin maker
initi coverag overweight initi coverag korea
botulinum toxin sector medy-tox tp outperform
hugel tp outperform excit secular
growth thank address market expans key region
oversea market entri k-toxin player seem immin expect
k-toxin player expand share botulinum toxin market
global market size estim bn medy-tox hugel
offici entri china allow k-toxin maker take
distributor margin off-shore agent also build brand equiti
sequenti entri global market us europ
like promis long-term growth albeit penetr
would depend region market partner medy-tox-allergan tie
innotox may progress time given competit global market
dynam street concern hugel near-term weak
seem overdon given schedul offici entri oversea market
start china
construct aesthet demand growth anticip
sale compound-annual-growth-rate medy-tox hugel thank on-going
export exist region well addit offici product shipment
china/us/europ requir local approv oversea growth
momentum justifi valuat trade
price-to-earnings medy-tox/hugel hugel top pick stock under-valued
valuat discount medy-tox risk includ delay
oversea approv progress competit among new entrant new
market risk relat partnership allergan medy-tox
us partnership hugel slow export exist channel
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
export usd exportschinau aesthetic-onli europ aesthetic-onli usd charl martineau pm univers toronto focu chart tabl
figur compani sale mixmedy-tox hugel
primarili engag sale botulinum toxin
compani data
figur k-toxin exportsmedy-tox hugel
combin showcas compound-annual-growth-rate
figur competit dynam global
botulinum toxin remain favour korean toxin
figur global market size estim bn
us/europ largest market
compani data credit suiss estim
k-toxin maker thank key market entri
china us europ
reach histor high
bloomberg professionaltm servic
toxinderm fillerothersu bn korea custom export datasum medy-tox hugel export hugelcagr hugelcagr m/sunadjustedprobability-adjustedmarketschinauseuropemarket bn aesthet largestallergan m/ entrantsyear entrymedy-tox player tbcmarketedmarket ipsen liquid discount/premiumhugel valuat discount medy-toxaverag average charl martineau pm univers toronto
offici launch china seem immin
offici entri k-toxin
player china
commenc
respect
expand margin
gain distribut
project botulinum toxin export compound-annual-growth-rate k-toxin player name medy-tox
hugel thank on-going export emerg market well entri key region
market china china rel small market share global one
fastest grow region estim market compound-annual-growth-rate next five
year expect offici entri k-toxin player china commenc
approv respect botulinum toxin product k-toxin maker may expand
margin could switch direct entri model current agenc model
k-toxin maker lack distribut margin believ medy-tox hugel
gain market share china given limit product offer grow demand
k-toxin enter develop market
limit impact
us/eu vs china
howev view
margin share gain
region
doubl k-toxin
address market
size expect
grow
medy-tox hugel
global botulinum toxin market estim bn nich market
secular growth driven therapeut aesthet usag us europ entri
next target k-toxin maker market share
market share market respect market domin three major
player allergan market share due high-entri barrier
sticki demand raw materi brand equiti howev global industri face
multipl new product launch us/eu maximum five includ medy-
tox hugel expect new product launch diverg strategi
across entrant depend botulinum toxin product featur competit
dynam differ develop emerg market expect k-toxin maker
limit impact us/eu vs china howev view margin share gain
region doubl k-toxin maker global botulinum toxin share next
five year address market size expect grow medy-tox
hugel
disagre market concern
tox find
progress
innotox pipelin
rebound
near
oppos
market seem still doubt medy-tox innotox launch allergan hold key
term us/eu commercialis base global competit dynam believ
allergan incentivis progress innotox clinic trial order defend
immin entri next-gener toxin long-act liquid-typ product
also posit hugel oper rebound near driven
acceler toxin export dermal filler market submiss china busi
normalis post bain capit acquisit whilst bake low
expec hugel us penetr rel posit europ entri
schedul believ hugel may leverag exist european partnership
croma leverag bain capit sale network stada call option
initi coverag
outperform
outperform
k-toxin maker
prefer laggard construct sector
initi coverag medy-tox/hugel tp outperform
expect secular growth k-toxin maker target price deriv mix
dcf mix includ pipelin valu post risk adjust proportion
clinic stage price-to-earnings methodolog mix oversea momentum result
ep compound-annual-growth-rate medy-tox hugel respect hugel
top pick trade histor high discount compar medy-tox despit
near-term futur growth potenti risk includ delay oversea
approv progress competit among new entrant new market daewoong
pharma etc risk relat partnership allergan medy-tox us
partnership transit hugel slow export exist channel
compani data bloomberg professionaltm servic consensu estim credit suiss estim
figur medy-toxoversea approv progress expect launch timelin
figur hugeloversea approv progress expect launch timelin
 vs vs vs toxin neuronoxapprov submissionlaunchchina ongoingapprov submissionlaunchu start expect launchu start approv submissionlaunch start expect launcheu start approv submissionlaunch endapprov submissionlaunchchina filler endapprov submissionlaunchu track submissionlauncheu endapprov charl martineau pm univers toronto figur valuat comparisonkorea biotechnolog sector peer global botulinum toxin peer
note price june outperform under-perform nc cover
compani data consensu estim cover compani credit suiss estim rest
companytickercountrymkt capturnovercspricetp price-to-earnings p/sale roe rel perf mn usd d-driven biotechshanmi biosimilars/cmosamsung aesthet botox d-driven aesthet botox biotech capturnovercspricetp price-to-earnings p/sale roe rel perf mn usd toxin player toxin player distribut charl martineau pm univers toronto
tabl content
focu chart tabl
offici launch china seem immin
k-toxin enter develop market
disagre market concern
prefer laggard construct sector
offici launch china seem immin
k-toxin player officialis china entri
competit dynam china
hugel china market potenti huge
view china toxin filler competit
k-toxin enter develop market
global market nich secular growth
overview global industri competit
view us/europ toxin competit
disagre market concern
medy-tox believ innotox launch
hugel oper rebound near
prefer laggard construct sector
medy-tox tp initi outperform
hugel tp initi outperform
prefer hugel medy-tox
botulinum toxin pipelin capac statu
korea biotechnolog sector holt
charl martineau pm univers toronto offici entri k-toxin
player china
commenc
approv
margin
offici launch china seem immin
k-toxin player officialis china entri
korean botulinum toxin export achiev compound-annual-growth-rate
korean toxin player achiev growth driven stellar export
asia emerg market requir rigor regulatori approv process
vs us europ on-going new market entri grow penetr
exist export region driver export growth
base korea custom data aggreg botulinum toxin export reach bn
current read export come medy-tox hugel
daewoong pharma commercialis nabota sale remain minim
compani focus key region expans us europ
fda/ema review botulinum toxin product
term export destin china account export valu
interestingli china yet approv korean botulinum toxin henc
presum export volum either redirect region hit chines
port absorb black market china custom data lack inform
final destin export product
figur botulinum toxin export korea
showcas compound-annual-growth-rate
figur region mix k-toxin export
note korea custom
toxin export sustain sequenti growth
export showcas compound-annual-growth-rate
export valu lh yoy growth rh usd korea custom export datasum medy-tox hugel export hugelcagr hugelcagr custom export datasum medy-tox hugel export charl martineau pm univers toronto
estim chines aesthet market botulinum toxin dermal filler still
rel small mn mn respect compar global
market botulinum toxin market estim bn howev found strong
growth momentum region botulinum toxin market estim grown
compound-annual-growth-rate sinc resili growth driven rise demand
beauti product help improv access aesthet treatment
botulinum toxin etc anticip botulinum toxin market deliv
compound-annual-growth-rate next five year
figur chinainject aesthet market
rel small botulinum toxin global
figur china botulinum toxin market
china market potenti substanti
understand china under-penetr term aesthet treatment includ
botulinum toxin procedur compar develop market us/eu
korea top number aesthet treament per capita global assum china
also grow substanti interest beauti care rise time although
lack latest data estim number plastic surgeri per capita
korea higher china
highest procedur per thousand
figur plastic surgeri per capitachina
one lowest procedur per thousand
k-toxin offici entri china market seem immin
current two approv botulinum toxin chinabotox allergan
btxa lanzhou institut biolog product local develop china medy-
toxin marketderm filler marketchina inject aesthet market size licens brand usd botulinum toxin market compound-annual-growth-rate charl martineau pm univers toronto
tox hugel either approv like submit market approv
cfda china fda follow daewoong among k-toxin player medy-tox lead hugel
term china entri view cfda approv expect expect
hugel follow right anticip cfda approv daewoong
pharma also recent commenc trial target
commercialis accord compani howev believ plan
seem aggress may face delay achiev initi target
compani recent initi trial
addit korean toxin develop understand global player ipsen also
attempt enter chines market compani conduct
clinic trial dysport glabellar line china market howev expect k-
toxin land china ipsen base develop clinic trial
figur upcom product pipelin china entri
partnership bloomag
partnership bloomag
partnership sihuan pharma
competit dynam china
k-toxin current export china
current botulinum toxin product export korean maker distribut local
agent china assum agent redistribut product authoris
botulinum toxin prescrib rule possibl penetr black
market consum estim china black market size larger offici
term product suppli current k-toxin manufactur export product fix
price lump-sum basi free inventori risk exchang local agent
full control price product market could long-term risk
brand equiti local agent may often lack sale strategi howev think offici
launch mid-to-long term posit event k-toxin player could gradual build
brand valu mainland china
market estim smaller black market
figur allergan botox chinaoffici
product segment china
given two brand far market segment premium allergan
botox low-end lanzhou btxa hengli product find upcom k-
toxin player like posit mid-tier product base
discuss compani lack detail ipsen compani succe
enter chines market would like posit product high-end sinc
global ipsen dysport price margin discount botox
figur botulinum toxin player chinaonli two approv product far upcom entri
biolog
studi allergan entri china
allergan botox approv chines regulatori author glabellar
line aesthet indic allergan access china market sinc thank
distribut partnership directli enter chines market shanghai
headquart present compani localis profession team
staff busi cover citi provinc across nation
accord allergan china allergan mainli focus ophthalmolog eye care
medic beauti segment though lack detail segment revenu contribut
allergan botox market share constantli risen botox gain
share within five year launch believ market appreci
botox strong brand equiti amid lack product applic k-toxin
product well still think market under-penetr
base media report sourc reuter allergan china record mn sale
yoy growth sourc detail allergan plan expand sale
mn china translat compound-annual-growth-rate believ
ambiti target explain surg aesthet demand china
figur allergan m/ chinaa rapid botox
market share expans sinc approv
growth plan deliv compound-annual-growth-rate
botulinum toxin aesthet treatment cost region
notic averag treatment cost botulinum toxin significantli differ region
offici data botulinum toxin cost price estim korea
domest aesthet treatment cost around per treatment clinics/hospit
china charg rang per treatment depend product
segment low-end premium product base estim note
aesthet treatment cost us around still way higher
treatment cost korea
figur overseassignific differ
margin direct entri warrant least asp k-
offici launch help gain distributor margin
believ offici launch k-toxin player china earn accret
toxin export like enjoy distributor margin current share local
agenc expect signific asp upsid k-toxin maker attempt direct entri
estim export shipment price around vial broadli equival
dose aesthet treatment per patient glabellar line etc modestli
assum gp margin clinic result least asp k-toxin maker
distribut
figur chinasummari model earn accret via offici entri
note cell shade base cs assumpt compani data credit suiss estim
partnership bloomag
medy-tox bloomag unlist privatis agre establish jv
medybloom china jv aim distribut medy-tox botulinum toxin
product neuronox dermal filler neurami etc requir regulatori
approv addit bloomag ha filler offer medy-tox bloomag equal
own jv ceo appoint bloomag chair bod
cfo appoint medy-tox
bloomag pure filler player access botulinum toxin
bloomag biotech aesthet solut provid vertic integr platform
inclus ha hyaluron acid raw materi product skin care product offer
bloomag own variou dermal filler brand botulinum toxin product
strateg allianc mutual benefici bloomag medy-tox
also note jv distribut medy-tox dermal filler plan segment
figur bloomagestrateg tie-up medy-tox enhanc aesthet
product offer addit botulinum toxin mid-seg dermal filler
botulinum toxin approv
medy-tox target suppli neuronox china partner directli vs current
agenc model help share distributor margin medy-tox file market
approv neuronox one three commercialis
botulinum toxin product medy-tox obtain cfda approv distribut
medybloom expect commerci launch would roughli take
month review although could subject chang
figur china botulinum toxin approv progressw expect medy-tox
meet product launch target
dermal filler approv follow
medy-tox conduct clinic trial dermal filler product neurami
lidocain aim market approv along botulinum toxin
product medy-tox suppli product china
hugel china market potenti huge
partnership sihuan pharma
hugel sign distribut agreement sihuan pharma botulinum
toxin botulax dermal filler chaeum product sihuan exclus
distribut right china full control price market hugel product
sihuan establish vast network nationwid hospit claim spot
term market share china domest hospit market compani major
therapeut area ccv cardio-cerebr vascular account sale
note sihuan diversifi revenu mix intern collabor
sihuan recent form jv suncro croma pharma
ownership ratio sihuan/croma jv sihuan enter
aesthet market start distribut croma dermal filler product princess
volum post obtain cfda approv
understand like concern china partnership given sihuan less
experienc aesthet market despit outstand nationwid hospit network
risk distribut network due implement two-invoic
two-invoic polici impli two invoic allow suppli chain
among manufactur distributor hospitalson manufactur
distributor distributor hospit polici brought
china govern order regul enhanc effici reduc illeg
behaviour drug distribut industri
howev believ sihuan sale botulinum toxin like remain solid thank
increas demand botulinum toxin aesthet indic lack supplier
current two licens product addit product medy-
tox hugel would still result four product offer total
figur sihuan pharma still one
strongest distributor china hospit market
despit rank declin
figur china healthcareimplement
two-invoic system announc could
impact distributor
botulinum toxin approv
hugel clinic trial botulax china market sihuan
pharma plan file market approv manag guid
botulinum toxin approv howev conserv factor approv
given slight delay progress assum clinic trial end
vs compani target
figur china botulinum toxin approv progressw factor conserv
outlook hugel product launch vs compani target
dermal filler launch
hugel complet clinic trial dermal filler product chaeum
current review studi compani guid file market submiss
within anticip approv howev also remain conserv
approv timelin modestli expect approv still hugel ahead
dermal filler approv race vs competitor medy-tox
view china toxin filler competit
market share gain botulinum toxin market
estim rapid market share gain k-toxin maker thank limit brand access
favour price medy-tox hugel plan posit mid-
segment allergan botox lanzhou btxa hengli still provid
much higher price vs current export asp model higher market share
medy-tox thank stronger sale network within market partner bloomag
although view hugel sale partner sihuan pharma may inferior aesthet
sale capabl still anticip solid market share gain believ seller
market see sign sihuan effort diversifi aesthet area sinc
like steadi penetr dermal filler market
although view china dermal filler market larger botulinum toxin market
think market crowd multipl player around ten player balanc
mix local foreign brand henc view chanc medy-tox hugel
gain presenc derma filler market slim compar botulinum
howev local partner medy-tox hugel bloomag sihuan respect
market botulinum toxin dermal filler product allow packag
product portfolio maximis sale capabl context expect greater
sale penetr hugel botulax sale partner like showcas higher
dedic less dermal filler line-up two brand princess croma
chaeum hugel compar medy-tox partner bloomag
seri dermal filler product offer posit medy-tox neurami one
mid-tier brand within group
china estim botulinum toxin dermal filler entri timelin
limit impact
us/eu vs china
howev view
margin share gain
region
doubl k-toxin
k-toxin enter develop market
global market nich secular growth
global botulinum toxin market size estim bn
estim global botulinum toxin market size bn
divid therapeut aesthet market therapeut market
mix larger aesthet market mix botulinum toxin driven
grow medicin use develop market us etc region us
singl largest market contribut global market sale follow europ
figur global therapeut market largest
figur region breakdown global botulinum
number botulinum toxin manufactur control global treati bwc
biolog weapon convent core raw materi bacteria clostridium
botulinum ban intern transfer current player right
bacteria reproduc commerci use player without right
enter industri
henc hand botulinum toxin manufactur global limit
number new entrant current global player market includ allergan
botox us/glob ipsen/galderma dysport europe/glob merz
xeomin europe/glob region player medy-tox neuronox korea
hugel botulax korea lanzhou institut btxa china
potenti entrant develop phase revanc us
daewoong korea
enter us market anticip event korea botulinum toxin
manufactur us largest market botulinum toxin global market size
bn anticip grow compound-annual-growth-rate driven
robust therapeut aesthet demand allergan hold averag market
share therapeut market share aesthet market share
respect bn size us market botox ipsen merz
compet allergan respect brand dysport xeomin
interestingli therapeut use larger aesthet use within us botulinum toxin
market due on-going indic expans migrain etc
therapeut market market bn share us bn charl martineau pm univers toronto figur us botulinum toxin market size
domin allergan botox
europ also anoth big market botulinum toxin estim market size
bn mix therapeut aesthet
segment also domin allergan aggress expand share
market share market share late estim
allergan sustain market share european peer ipsen player
merz combin form higher share europ us
figur europ botulinum toxin market size
domin allergan botox
develop market differ emerg market
therapeut use botulinum toxin key featur differenti develop market
us europ etc emerg market asia latin america etc sever
sub-seg within therapeut market primarili requir regulatori approv
per indic patient elig reimburs therapeut treatment
depend condit howev aesthet use reimburs base
cash-pay fda/ema approv aesthet indic crow feet glabellar line
also off-label treatment area facial aesthet
indic requir botulinum toxin maker
note revanc ir credit suiss research
figur aesthet marketfaci treatment
key segment usual cash-pay
overview global industri competit
summari us/europ entrant includ k-toxin
multipl new entrant us europ market entri begin
earli aesthet market seem crowd compar
therapeut market current us europ market domin three
key player name allergan botox ipsen dysport merz xeomin among
three allergan retain domin share ipsen merz combin estim
captur share us europ respect
figur summari competit outlook us/eu market
new product entri
entri year entrant
five new product seek entri us/eu market
three player two k-toxin manufactur one us-bas manufactur plan
us eu market entri player clinic trial henc
separ new brand launch schedul exist player ipsen
global botulinum toxin player compani prepar multipl next-
gener pipelin among next-gener toxin dysport solut also
regard new product launch view allergan like proceed
commercialis medy-tox innotox pipelin world first liquid-typ toxin
in-licens back follow text built thesi base
assumpt allergan progress innotox commercialis
muscl movement migrain bladder hyperhydrosi charl martineau pm univers toronto figur upcom product pipelin us/eu entri
commercialis
commercialis
start
commerci
commerci
commerci
limb spastic chronic migrain
partnership
in-licens allergan
commercialis
section detail featur botulinum toxin product market brand
anticip new product well like market strategi new entrant
product differenti clearli differ among product regard
botulinum toxin major market product base botulinum toxin
type seven typesa differenti factor includ molecular
weight pharmaceut form either powder requir reconstitut liquid
ready-to-us form exist animal-/human-deriv vehicl human
serum albumin etc storag condit usual requir refriger etc
characterist lead entrant determin strategi market
appeal similar vs differ botox base product profil
anticip featur product similar botox hugel botulax
etc may aim demonstr similar botox doctor patient
instanc daewoong nabota molecular size kd
product featur reconstitut procedur etc botox conduct seri
studi total sampl size us/eu trial showcas
safeti efficaci also non-inferior botox howev product
molecular weight longer durat etc medy-tox innotox liquid-typ
human albumin storag conveni etc may plan differenti
botox appeal advanc featur market
charl martineau pm univers toronto figur product descriptionnew product pipelin us/eu entri
figur daewoong nabota clinic trialsevolu market partner daewoong intend
showcas non-inferior botox well proven efficaci safeti placebo
nabota us studi
nabota us studi
nabota us studi
nabota us studi
nabota us studi
doubl blind activ
low-end vs premium segment posit base aforement analysi
expect upcom product similar product featur posit
lower price vs botox exist product like applic
hugel botulax per check compani well daewoong
nabota accord media report sourc dailypharm howev product
differenti featur may seek posit par higher price
market product view
sale partner fact one import featur new entrant
believ strong market strategi crucial order penetr market
pre-domin major player gener view new entrant
inferior sale network far compar exist player allergan
staff global regard us market although lack exact
breakdown us sale forc ipsen merz player us
staff respect total us
sale organis
current held croma
staff us
manag seek
plan build sale
plan return
partnership larg
distribut right
repres prior
perform us
player close
croma staff
botulinum toxin m/
brand dysport
europ botox brand
stada pan-european
sale network
view us/europ toxin competit
market share assumpt medy-tox hugel us/eu
base sell-through estim medy-tox hugel botulinum toxin product
factor respect market share us/europ base follow
therapeut usag liquid toxin model innotox captur low-teen
digit market share therapeut market us europ believ
liquid-toxin provid favour featur therapeut treatment accur dose
requir reconstitut undisturb dilut process
applic therapeut indic allergan may launch innotox select
therapeut indic believ may face challeng new entrant
applic aesthet indic liquid toxin howev believ liquid
form may limit benefit aesthet treatment requir flexibl
botulinum toxin dosag dilut process depend patient condit
regard believ allergan rush bring two brand
aesthet field patient tend tie botox brand equiti rather switch
newer product unless signific financi benefit
higher market share us vs eu innotox anticip innotox
leverag allergan strong sale network global howev us
europ believ allergan higher influenc us market
limit access us aesthet market hugel particularli
excit hugel us penetr moment due lack sale partnership
believ price merit us peer allergan ipsen merz
compani may plan debut lower price outcom substanti
hugel higher chanc europ penetr model higher market
share hugel aesthet europ thank price merit well sale
partnership local partner croma compani extend busi
cooper stada botulinum toxin dermal filler product although
croma rel smaller compani believ partnership larger
compani stada help penetr market extent
figur medy-tox innotox market share
figur medy-tox innotox market share
figur hugel botulax market share us
figur hugel botulax market share europ
global market share gain driven expans key market
estim medy-tox hugel expand global botulinum market share
respect next five year mainli driven entri key
market china us europ
share base sell-through revenu
base sell-through revenu
typic develop market us/eu etc larger portion therapeut market
aesthet market mix emerg market domin aesthet
applic view new entrant may differenti us aesthet
market depend brand price strategi view posit new
entrant follow segment
low-end segment current two k-toxin maker one us-bas manufactur
plan us entri daewoong hugel korea dedic
aesthet market henc believ daewong nabota hugel
botulax may compet low-end segment like leverag price
given high price botulinum toxin treatment us estim us
treatment cost patient amount averag higher
korea
high-end segment us-bas botulinum toxin marker revanc seem
differenti k-toxin entrant product demonstr
longer-act profil compar market product botox accord
compani patient mostli favour longer-act toxin revanc plan
launch high-end product compet exist product separ
believ allergan may progress commercialis innotox
aesthet market could cannibalis botox franchis
figur botulinum toxin player entrant us aesthet market
premium high-end
competit threat less sever us therapeut market mani entrant seek
penetr aesthet market per respect compani strategi
limit entrant revanc entrant expect launch product
therapeut indic seem revanc target launch
aesthet market launch therapeut market daewoong
hugel plan therapeut indic allergan market innotox
therapeut use like plan defend revanc longer-act
figur botulinum toxin player us therapeut market
premium high-end
european market dynam remain similar us regard higher therapeut
market share competit fierc european aesthet market
maximum four entri
low-end segment k-toxin player also target european launch
like us market daewong nabota hugel botulax may compet
low-end segment plan launch product aesthet market
high-end segment ipsen prepar launch liquid-typ toxin ex-u
region would like fit high-end segment given advanc
technolog revanc plan enter european market soon us entri
reason assum revanc launch high-end given
differenti featur line view us market assum allergan
commercialis innotox pipelin european market
figur botulinum toxin player eu aesthet market
premium high-end
competit milder european therapeut market entrant
plan therapeut launch
competit among advanc toxin anticip two entri start
ipsen target launch liquid-typ toxin dysport solut base
advanc technolog albeit three-year gap revanc plan enter market
longer-act toxin like us model align view
allergan may commercialis innotox europ in-licens medy-
figur botulinum toxin player eu therapeut market
premium high-end
figur us botulinum toxin aesthetic/therapeut market
note botulinum toxin compani data credit suiss estim
figur eu botulinum toxin aesthetic/therapeut market
note botulinum toxin compani data credit suiss estim
aesthet allerganbotoxmarketedipsendysportmarketedmerzxeominmarketedentr aesthet daewoongnabotacrl ongoingapprov start expect track therapeut allerganbotoxmarketedipsendysportmarketedmerzxeominmarketedentr therapeut daewoongnabotano plan submiss schedul start approv submissionlaunch plan aesthet allerganvistabelmarketedipsenazzaluremarketedmerzxeominmarketedentr aesthet daewoongnabotaund approv reviewlaunchipsendysport solutionlaunch liquid-typ toxin addiiton exist product ongoingapprov start expect endapprov therapeut allerganbotoxmarketedipsendysportmarketedmerzxeominmarketedentr therapeut daewoongnabotano plan launchipsendysport solutionlaunch liquid-typ toxin addiiton exist product submiss schedul sharedlaunch start approv submissionlaunch plan charl martineau pm univers toronto
disagre market concern
tox make
progress
innotox pipelin
rebound
near
oppos market
medy-tox believ innotox launch
licence-out deal allergan
medy-tox licens innotox pipelin allergan global distribut
exclud korea japan market total cost mn mileston
contract also includ royalti product fee proportion innotox commerci
sale innotox develop stage later approv
launch korea medy-tox oversea commercialis innotox
entir depend allergan decis
figur innotox licence-out dealmileston detail sale fee structur
sale royalti proportion commerci sale
manufactur fee product suppli exclus
remain mileston amount mn
fulli receiv
partial payment mn receiv upon progress clinic trial
term undisclos elig commerci launch
undisclos assum within rang low-to-mid teen-digit
innotox special
medy-tox innotox known innov product follow reason
liquid formul innotox first liquid toxin among botulinum toxin a-typ
botulinum toxin product powder form benefit liquid form
divers includ user-friendli featur requir dilut process
 powder-typ go serin reconstitut etc result innotox
maintain accur dose undisturb dilut process
non-anim compound recent success stabilis agent
botulinum toxin animal-deriv protein human serum albumin gelatin
import sinc toxin may use month composit
formul henc toxin must stabilis stabilis agent howev
presenc animal-deriv protein final formul present potenti problem
certain stabl virus prion infecti pathogen compound carri
donor contamin toxin
free human serum albumin usual albumin appli bulk carrier
stabilis neurotoxin complex prevent aggreg surfac
howev certain case human serum albumin put patient potenti risk
receiv blood-born pathogen infecti agent innotox howev free
albumin use substanc methionin polysorb sucros
stabilis
made allergan tie medy-tox
estim allergan hold market share global botulinum toxin market
henc numer attempt peer overcom allergan domin
global player ipsen challeng allergan vow develop
next-gener toxin liquid formul vs convent powder-typ toxin ipsen
close make entri us market liquid-typ product
fda allow undergo approv pathway current form henc ipsen
aim launch liquid toxin europ ex-u region
howev certain reason insuffici data support etc ipsen liquid-typ toxin
yet commercialis even region would rule
possibl could trigger allergan tie medy-tox
innov toxin product innotox also liquid-typ toxin
also interest find allergan innotox in-lic came ipsen
acquisit syntaxin commit develop recombin botulinum toxin
technolog note late ipsen develop anoth next-gener
product recombin toxin base technolog acquir syntaxin
figur happen medy-tox-allergan collabor
key event allergan ipsen
ipsen acquir syntaxin uk-bas compani lead research recombin botulinum toxin technolog
ipsen announc clinic result intend file first ready-to-us liquid toxin europ row
us fda allow approv pathway ipsen liquid toxin
ipsen partner galderma market distributor botulinum toxin dysport us etc
prolong concern innotox clinic trial
order allergan commercialis innotox must go clinic trial medy-
tox alreadi conduct clinic trial australia therapeut
cervic dystonia aesthet indic glabellar line howev
progress clinic trial sinc complet henc debat
around allergan medy-tox regard innotox date back bear argu
allergan intent commercialis medy-tox innotox pipelin in-
licens pipelin ban us global market entri bull illustr rosi
earn potenti medy-tox allergan commercialis innotox global
figur medy-tox went oversea clinic trial innotox
innotox australia studi
innotox australia studi
therapeut indic
aesthet indic
increas expect innotox clinic trial
may anoth local report sourc korea herald claim
innotox clinic trial progress articl cite respons directli
allergan hq argument support korean custom data may
data showcas botulinum toxin export ireland allergan hq locat
dublin first time histori follow articl cite medy-tox offici sourc
moneytoday admit botulinum toxin export ireland belong
albeit confirm whether innotox
figur event relat innotox clinic trial
medy-tox complet clinic trial aesthetic/therapeut innotox australia
medy-tox complet construct plant dedic manufactur innotox
allergan host day innotox found stage
allergan comment progress clinic trial innotox
medy-tox ceo said delay innotox clinic trial due lack medy-tox meet facil standard
allergan agre class doctor claim allergan kept innotox enter us market
allergan comment host day updat botulinum toxin pipelin strategi
korean press interview allergan hq offici report intent progress innotox trial
next-gener toxin entri follow us europ
look toward number new entrant us european market
next three year initi daewoong pharmaceut partner
daewoong nabota target aesthet market lack indic
therapeut market like daewoong focu low-incom potenti
aesthet adopt leverag price discount
interest entri revanc us europ market
well ipsen retrial liquid-typ toxin commercialis ex-u region
revanc prepar launch us follow europ
longer-act toxin last doubl period montha vs
botulinum toxin accord compani aim commerci
therapeut market henc revanc undergo clinic trial
ipsen dysport solut ipsen known market brand dysport
accord compani plan launch liquid-typ botulinum toxin call
dysport solut anoth novel botulinum toxin improv
offer ready-in-us form requir reconstitut process
year entri
year entri
allergan set defenc next-gener toxin
believ chanc allergan would incentivis launch medy-tox
innotox allergan neither progress clinic trial commit
commercialis innotox publicli market wonder
commerci launch innotox
view chanc favour medy-tox like progress
innotox clinic trial allergan near futur believ on-going attempt
competitor develop next-gener toxin liquid formul recombin
longer-act toxin etc eventu trigger allergan commercialis innotox
could market premium product given overwhelm featur
figur latest toxin develop could concern allergan
revanc partner develop manufactur biosimilar botox
ipsen intend file liquid toxin ex-u within get approv
allianc daewoong pharma reiter would commercialis low-cost botulinum toxin us
factor innotox launch
built model commercialis innotox
us europ assum clinic trial commenc
therapeut studi rule aesthet product launch model three-
year time go year approv pathway year
result market approv
also await updat allergan compani offici comment host
 day regard botulinum toxin develop strategi anticip
event reveal intent innotox clinic trial
figur allergan day
includ pipelin asset
figur develop medy-tox
market innotox korea
charl martineau pm univers toronto figur medy-toxestim innotox clinic trial commercialis timelin
supplement timelin key event sinc innotox deal
detail follow key theme player surround allergan medy-tox
ipsen challeng allergan ipsen botulinum toxin player
constantli reveal plan expand us market develop
next-gener toxin liquid-typ order compet allergan initi attempt
us expans success thank new market partner galderma
sinc liquid toxin pipelin face unfavour respons fda
commercialis
allergan intern disrupt allergan acquir actavi lead
biopharma compani strength gener over-the-counter over-the-count market
merg entiti assum name allergan global brand soon follow sale
gener busi teva also attempt merg
allergan howev pfizer-allergan deal termin
medy-tox slow progress innotox commercialis partnership
allergan medy-tox progress studi innotox also
complet plant innotox-ded facil howev innotox
clinic trial progress due medy-tox inabl meet product
standard suggest allergan
start expect entri among new start approv submissionlaunch entri among new start expect entri among new entrantsipsen dysport start approv submissionlaunch entri among new entrantsipsen dysport charl martineau pm univers toronto figur event dynam around allergan
sinc found number new threat around allergan new player
progress commercialis new botulinum toxin product
ipsen on-going effort ipsen fail commercialis liquid toxin far
re-affirmed intent market sever next-gener toxin includ liquid-typ
recombin toxin
new threat materialis sinc evolus-daewoong collabor file
bla low-end botulinum toxin product nabota aesthet indic
long-act version toxin reveal plan enter aesthet
therapeut market
multipl signal innotox clinic trial medy-tox claim readi
innotox clinic trial plant meet product standard suggest
allergan progress howev
syntaxin recombin toxin technolog sepin-licens medy-tox innotox liquid-typ toxin licens innotox right mn milestonedeccomplet studi innotox therapeut indic clinic result liquid toxin data therapeut aesthet indic febu fda provid ipsen liquid toxin approv pathwaymaycomplet construct plant innotox-ded facil valeant announc sell us/canada right dysport aesthet brand nestl galderma parent compani julpartn galderma distributor ipsen toxin product usnovactavi gener drug maker announc acquir cosmet surgeon file complaint allergan assert in-licens innotox order prevent impend entri usmaractavi complet allergan acquisit adopt allergan new global namejulteva gener drug maker announc acquir allergan gener businessth us sale partner galderma suffer us aesthet market due larg inventori build predecessor valeant galderma complet acquir right dysport etc us/canadanovhost day innotox found acquir anterio clinic stage biotech develop topic botulinum toxin product merger agreement allerganjulipsen updat plan file liquid formul europ aesthetic/therpeut market still wait stabil dataaugdur call allergan announc progress clinic trial innotoxoctmedy-tox challeng suspicion local competitor regard origin botulinum toxin strainsnovceo admit delay progress innotox clinic trial due medy-tox difficulti meet plant manufactur charl martineau pm univers toronto
us market
allergan agre settl lawsuit class doctor claim kept
innotox enter
commercialis korean press interview sourc korea herald allergan
hq offici cite allergan intent progress clinic trial allergan
offici comment host day disclos botulinum toxin
develop strategi anticip illustr plan innotox
rais hope
figur event sinc threat allergan botox multipl player
assur innotox clinic trial medy-tox final allergan manufactur inspect plant return busi disrubt ipsen/galderma us aesthat businessipsen aim recombin toxin compet allergan maydur investor day ipsen introduc next-gener toxin pipelinesevolu sale partner daewoong file bla approv us fda nabota aesthet indicationsjunmedy-tox file civil lawsuit daewoong alleg theft botulinum toxin strainaugdur call allergan includ innotox upcom pipelinedecrev releas posit data botulinum toxin aesthet partner develop manufactur biosimilar botoxfeballergan agre class doctor settl alleg allergan inflat botox price keep innotox us marketreaffirm file liquid toxin ex-u approv call allergan comment host day medic aesthet day updat botulinum toxin pipelin strategyrev host investor day updat botulinum toxin pipelin develop progressmayloc press interview allergan hq offici report allergan intent progress clinic trial innotoxdaewoong approv cgmp fda botulinum toxin product product charl martineau pm univers toronto
hugel oper rebound near
oper rebound near
hugel share price correct term correct
market concern medy-tox rampant domest price cut fight hugel
domest market share hugel defend well throughout market gain
confid hugel oper share price rebound accordingli howev
slower export botulinum toxin disappoint export dermal filler
trigger anoth price correct result market lose confid
hugel howev follow argument market concern
botulinum toxin export still robust hugel export botulinum toxin
soft yoy vs yoy howev observ key region
export robust yoy vs yoy compris asia ex-japan latin
america eastern european countri view period export gain
minor region would weigh high base export
robust key region
offici china launch dermal filler hugel run ahead
dermal filler develop approv race china compar toxin peer
 medy-tox hugel file dermal filler approv like
approv upcom product approv could allevi market concern
slow export asian region believ recent news sourc
moneytoday china stricter import control could impact hugel weak
filler sale yoy vs yoy view
major sale greater china region would driven daigong
bain capit acquisit pmi impact also view recent weak
export could somewhat attribut hugel on-going post-merg integr
pmi effort sinc bain capit take-over hugel gone number
intern chang sinc would neg impact recent
oper albeit temporari event hugel appoint new ceo nov-
follow sale organis chang accord compani new
division sale head join team april henc believ pmi
process would gradual fade progress
hugel may benefit stada-croma partnership
point hugel-stada relationship croma pharma privat
own aesthet compani specialis dermal filler product distribut croma
hold right distribut hugel botulinum toxin product sinc year
hugel made agreement croma stada got access hugel botulinum toxin
product sign busi partnership croma pharma
partnership made far ahead bain capit invest
hugel stada bain capit acquir stake stada follow
acquisit hugel year practic stake
figur relationship hugel stadahugel could leverag botulinum toxin europ
croma pharma sign ten-year distribut agreement hugel
stada strengthen aesthet pipelin croma filler product
botulinum toxin product eu us australia
stada arzneimittel brief
princess well access hugel botulinum toxin product
bain capit join bid stada
bain capit agre invest mn hugel gain control
bain cinven jointli acquir stake stada bn
stada mainli focus over-the-counter mix prescription-bas brand drug
mix wide rang sale network europ result revenu
compani posit toward non-cycl pharmaceut market whilst
late expand product portfolio select biosimilar futur growth although stada
lack aesthet busi experi believ pan-european sale network
like help hugel botulinum toxin product penetr approv ema
figur comparison exist botulinum toxin manufactures/distributor
hugel european sale partner
hugel posit bain capit healthcar portfolio
bain capit privat equiti bain capit acquir control stake hugel
invest vehicl lidac leguh issu design activ compani
view call option hugel may seek potenti synergi bain
capit global-wid healthcar portfolio view hugel stand within
portfolio given uniqu product offer botulinum toxin vs compani
figur bain capit privat equiti healthcar portfolio
date
gener drug maker domest export gener
one largest healthcar provid brazil
jun manufactur botulinum toxin dermal filler manufactur aesthet inject
expect much upsid hugel us entri moment mainli due
partnership risk distribut right current held croma
addit clinic trial hugel commun market proceed
addit clinic trial us make total two track us
market total sampl clinic trial ad programm
target addit clinic trial increas number patient
sampl like around compani state decis made upon
consult peer third-parti cro contract research organis
figur hugel global trial botulax conduct croma
sale partner us/europ
botulax global studi bless
botulax global studi bless
aesthet indic
aesthet indic
activ recruit
activ recruit
chang us partnership hugel sale partner confirm yet
current austria-bas croma hold hugel botulinum toxin market right
us sale howev hugel plan either switch us partner proceed
either way requir hugel request market right return croma
involv addit cost croma fund clinic trial
behind competit race us new clinic trial plan submit
market approv allow commercialis best
show two-year delay compar initi studi design
finish clinic trial current review data announc
made investor concern futur growth daewoong spearhead
us market accord daewoong manag
partnership matter entri date develop market despit
market percept daewoong earlier entri us market
concern time entri believ daewoong
establish local partner would make minim impact us penetr
neither hugel make impact current partnership structur
track entri among new endapprov entri among new entrantsdaewoong charl martineau pm univers toronto initi coverag
outperform
outperform
growth k-toxin
prefer laggard construct
medy-tox tp initi
price base mix dcf price-to-earnings methodolog
deriv target price base mix dcf price-to-earnings approach
ratio way attempt captur futur pipeline/earn valu
near-term earn momentum target price also suggest blue/grey sky
scenario tp appli differ factor key pipelin approv statu etc
figur medy-toxtarget price scenario analysi
dcf approach busi valu adjust probabl
order deriv core busi valu appli dcf adjust probabl
pipelin product depend approv statu submit
approv etc applic key pipelin project includ innotox
us/eu region approv china entri botulinum toxin dermal filler approv
adjust approv uncertainti innotox china account
medy-tox npv net present valu respect base case translat
fair valu respect
view allergan progress innotox pipelin clinic trial
complet alreadi appli approv probabl base case
us/eu launch china project botulinum toxin file approv dermal
filler clinic trial pipelin differ phase appli
approv probabl respect base case
non-cor asset valu china jv medybloom base
dcf adjust ownership approv uncertainti base case
dcf valuat core busi appli wacc termin growth rate
dcf valuat china jv businessappli wacc termin growth rate
dcf valuat product royalti chang work capital-expenditure incl discount present valu termin valu tv present valu termin growth approach termin growth rate termin valu discount factor busi fair valu valu mixno present value-per-share termin value-per-share krw jv work capit discount present valu termin valu tv present valu termin growth approach termin growth rate termin valu discount factor jv fair valu risk china jv fair valu valu mixno bn china jv fair value-per-share present china jv fair value-per-share krw termin china jv fair value-per-share krw charl martineau pm univers toronto
price-to-earnings approach appli histor high-end price-to-earnings base case
term price-to-earnings approach medy-tox trade rang averag
std standard deviat std sinc base histor consensu
estim appli histor high-end valuat averag std core
oper remain solid gain confid oversea launch china etc
np major bn
fair valu base price-to-earnings bn
histor share price price-to-earnings valuat rang
bloomberg professionaltm servic
bloomberg professionaltm servic
hugel tp
initi
price base mix dcf price-to-earnings methodolog
deriv target price base mix dcf price-to-earnings approach
ratio hugel share busi model medy-tox botulinum toxin
dermal filler henc also valu hugel consist methodolog
medy-tox base case blue/grey sky scenario etc
figur hugeltarget price scenario analysi
dcf approach busi valu adjust probabl
also adjust probabl pipelin project deriv dcf valuat
hugel compani conduct number clinic trial botulinum toxin
market china eu us pursu approv dermal filler china
well botulinum toxin pipelin stage clinic trial henc
appli approv probabl china eu us dermal filler
project china hugel progress file deserv probabl
adjust approv uncertainti china project botulinum toxin dermal filler
claim largest portion npv among pipelin follow europ
us base case translat fair valu
respect
factor non-cor invest asset could find asset
signific enough acknowledg upcom ipo one hugel
invest asset olyx stake seem non-materi event hugel
ipo prospectu state market cap bn base subscript price rang
dcf valuationappli wacc termin growth rate
dcf valuat product royalti chang work capital-expenditure incl discount present valu termin valu tv present valu termin growth approach termin growth rate termin valu discount factor busi fair valu busi fair valu bn valu present termin value-per-share charl martineau pm univers toronto
price-to-earnings approach appli histor averag price-to-earnings base case
ipo hugel also trade rang averag
std standard deviat std sinc base histor consensu
estim hugel oper weak late appli averag rang
histor valuat expect gain confid progress
np major bn
fair valu base price-to-earnings bn
histor share price price-to-earnings valuat rang
bloomberg professionaltm servic
bloomberg professionaltm servic
prefer hugel medy-tox
hugel trade discount medy-tox
construct growth botulinum toxin thank on-going oversea
market expans limit number new entrant howev medy-tox
hugel prefer hugel due undemand valuat although share
histor hugel trade discount medy-tox base consensu forward
price-to-earnings valuat sinc averag discount read seem
explain medy-tox divers botulinum toxin ip product hugel
partial due rel superior market partner china us/eu
bring market higher confid medy-tox oversea penetr compar
forward consensu p/eavg sinc charl martineau pm univers toronto figur medy-tox vs hugelactu forecast
compound-annual-growth-rate botulinum toxin sale
figur medy-tox vs hugelactu forecast
averag botulinum toxin sale mix total
discount gap seem fairli stretch
follow aforement discount factor hugel valuat discount medy-tox
seem sever discount risen histor peak late think
market seem concern delay hugel us entri slower
oper dermal filler export domest botulinum toxin investor
seem build like progress innotox clinic trial medy-tox
howev believ concern seem overdon believ hugel direct market
entri china secur multi-year growth outlook seem immin dermal
filler approv botulinum toxin approv
bloomberg professionaltm servic
bloomberg professionaltm servic
figur hugel vs medytoxhugel discount reach histor high
bloomberg professionaltm servic credit suiss research
discount/premiumhugel valuat discount medy-toxaverag average charl martineau pm univers toronto
delay oversea approv progress
medy-tox hugel target multipl entri key oversea market
vulner approv risk henc alreadi factor statist approv risk
per approv statu pipelin pipelin close approv gener
anticip approv year post initi market submiss
could delay due unexpect reason instanc daewoong pharma
anoth k-toxin market lead us/eu entri race recent receiv
complet respons letter us fda report
defici chemistri manufactur control seem minor issu
howev compani expect launch delay month although year delay
alter dcf-deriv valuat much medy-tox hugel
necessarili believ entri timelin matter us/eu howev could
critic compani fall behind race enter china lead
entrant competit edg captur rapidli grow market
competit among new entrant new market
total five entrants/product head us/eu market chanc
competit could get fierc could take form asp cut instanc
reason korea low botulinum toxin asp mainli increas competit among
local player china/us/eu seem manag higher thank
limit number player
howev less concern risk moment china market
rapidli grow competit milder korea market get
satur also us eu sinc market divid aesthet
therapeut competit dynam evolv differ expect stricter
competit aesthet market risk seem manag initi asp set
much higher korea henc aesthet player hugel may set price
discount exist player gain share rather compet new entrant
segment
although anticip progress medy-tox-allergan tie-up understand
medy-tox free risk associ partnership allergan
therefor remain conserv factor innotox commercialis
conserv assum late launch around also assum
launch therapeut market believ unlik allergan
launch two brand aesthet market
hugel asid rel weaker partner profil vs medy-tox us
partnership risk remain given uncertainti hugel-croma agreement etc even
hugel return distribut right croma visibl new
partnership henc model minim share gain hugel us
slow export exist channel
believ major medy-tox hugel valu lie exist export
channel oversea exclud china us europ base npv
dcf-deriv valu medy-tox hugel respect form botulinum
toxin export therefor slowdown export could result signific downsid
share price case hugel post releas softer export
botulinum toxin pipelin capac statu
medy-tox total three botulinum toxin product
global product neuronox sold
world first liquid formul botulinum
countri sinc first launch
toxin type licens allergan
obtain coretox market approv
neuronox sold world-wide regist
develop botulinum toxin
countri registr progress
type product coretox
launch korea market
neuronox line consist
contain anim sourc human
coretox advanc new botulinum toxin type
unit offer variou choic accord
serum albumin provid trait user
product exclud anim deriv hsa
applic physician find easier use
friendli proven efficaci safeti clinic studi
non-toxin protein ingredi
patient econom
accur dose
prevent immun system develop
antibodi would eventu wear
effect botulinum toxin type
ampl capac readi k-toxin maker
medy-tox total three plant korea latest plant commercialis
aggreg capac amount tn base manufactur sale
includ innotox-ded plant
hugel recent doubl capac plant commercialis
although total capac read medy-tox total capac inclus
innotox-ded plant seem suffici enough hugel product
base impli utils rate
figur medy-tox hugel gone
capac expans
figur impli utilis rate suggest
medy-tox group organis manag profil
medy-tox straightforward organis structur core busi conduct
parent entiti subsidiari korea japan sale distribut
thu illustr organis chart
figur medy-toxboard director
year birth descript
date expiri
head
head manufactur
file compani data credit suiss research
hugel group organis manag profil
hugel also simplifi organ structur hold two key subsidiari across
ab februari hugel merg hugel pharma
own subsidiari engag domest market sale hugel aesthet
product hugel meditec subsidiari distribut hugel
ab stake subsidiari specialis modif hugel
figur hugelboard director
year birth descript
date expiri
bod bain capit file
member audit committe
outsid director member audit committe
outsid director member audit committe
establish microbi toxin centr medytox
obtain kgmp approv medytox plant ochang
obtain approv kfda korea first world fourth botulinum toxin type meditoxin
first regist meditoxin oversea market bolivia product name neuronox
achiev market share botulinum toxin market korea
list kosdaq
receiv ce mark hyaluron acid filler neurami deep
obtain kgmp approv filler depart medytox plant ochang
groundbreak cgmp compliant medytox plant ii osong
obtain approv mfd neurami deep
obtain approv mfd world first non-animal-deriv liquid formul botulinum toxin type innotox
sign licenc agreement allergan inc us new formul new botulinum toxin type
complet medytox plant osong construct biggest scale korea
obtain drug approv non-animal-deriv botulinum toxin type refin main activ ingredi coretox
succeed purifi botulinum toxin type protein
implement preclin test botulinum toxin type protein
instal kgmp system factori techno park chuncheon
receiv approv manufactur pharmaceut
obtain bn invest privat equiti fund ibk industri bank korea
first export japan
commercialis botulax domest market
initi approv process intern commercialis
complet construct cgmp/eugmp compliant sceond facil chuncheon g-tech
complet registr second chuncheon factori cgmp eugmp
commercialis chaeum filler
receiv ind approv phase clinic trial botulax usa
receiv ind approv phase clinic trial botulax germani poland
receiv ind approv phase clinic trial botualx china
chang largest sharehold leguh issuer design activ compani
merger hugel pharma hugel meditec
korea biotechnolog sector holt
holt methodolog use proprietari perform measur known
return invest cfroi approxim econom return
estim averag real intern rate return earn firm portfolio
project constitut oper asset firm cfroi directli compar
real cost capit investor real discount rate see firm creat
econom wealth remov account inflat distort cfroi allow
global compar across sector region time also comprehens
metric tradit roe
histor forecast cfroi trend botulinum player price
reason expect despit higher similar cfroi level
recent year characteris high
major biotechnolog cover report gener shown valu creativ
compound double-digit growth asset base instanc medy-tox constantli
deliv econom return grow capit base per annum
hugel trade cfroi triple-digit growth sever year celltrion stock
rel modest level growth improv corpor profit
figur summaris histor achiev firm also depict
current level forecast return market long-term expect
ahead botulinum toxin name medy-tox hugel price level
econom return next five ten year similar current forecast level celltrion
group stock price much demand expect mark green dot
indic aggress valuat biosimilar compani current price
figur botulinum toxin player medy-tox hugel price rel reason expect
compar biosimilar compani celltrion inc celltrion hc
figur also illustr differ valuat two group holt price-to-earnings
measur market apprais valu ad holt price-to-book rel profit
cfroi botulinum toxin name particular hugel trade signific rel discount
biosimilar name even though profit growth profil par
figur botulinum toxin name trade much lower in-lin valuat histori
biosimilar trade stretch histor high valuat
number share mn
price month
botulinum toxin manufactur korea found medy-tox
richest histori among botulinum toxin player korea
recent capac addit also largest capac among peer vs
hugel also assess strongest pipelin given three
differ type botulinum toxin market alreadi medy-tox also
on-going export growth fuell latest capac addit medy-tox
three plant korea plant plant ad
respect plant dedic allergan partner innotox
commercialis assum plant commit domest
oversea oper includ direct entri china partner
bloomag expect offici shipment china mainland
compani file market approv botulinum toxin
allergan partnership shine last overhang risk allergan could
remov believ allergan could incentivis
launch innotox sinc in-licens pipelin believ
allergan could choos innotox defend next-gener
toxin liquid-toxin launch ipsen long-
act toxin launch revanc anticip
detail schedul allergan day
ride recent momentum initi outperform rate
target price base mix dcf price-to-earnings methodolog
valuat around histor higher-end averag std due
strong earn deliveri believ on-going growth
momentum justifi see higher upsid potenti china entri vs
innotox pipelin given greater market potenti grow market
two player higher chanc approv
valuat metric
chg prev ep
price rel chart measur perform
kosdaq se kosdaq min inx close
spot exchang rate
figur medy-toxexport destin
good sold
profit tax
free cash flow firm
net chang cash
medy-tox inc biopharmaceut compani compani
research develop manufactur product use clostridium
botulinum micro-organ toxin
bull case tp deriv mix dcf
price-to-earnings valuat factor approv
chanc china product launch toxin/fil innotox
commercialis us/eu/row also appli
higher price-to-earnings multipl averag standard deviat
bear case tp deriv mix dcf
price-to-earnings valuat factor approv chanc
china product
commercialis us/eu/row also appli lower
price-to-earnings multipl averag standard deviat histor
toxin/fil
price rel chart measur perform kosdaq se
kosdaq min inx close
spot exchang rate
number share mn
price month
medy-tox scale oversea expans scheme despit debut
later medy-tox hugel success market botulinum toxin
product botulax claim larger toxin sale medy-tox
oversea direct entri off-set recent oper woe hugel
output sinc slower sale toxin filler
yoy vs aggreg yoy due extern factor
control daigong etc howev believ concern like
lift hugel seek direct entri china expect
offici filler approv faster medy-tox follow toxin
approv
bain capit synergi call option hugel plan market botulinum
toxin product europ us follow
oversea
partnership anticip share gain europ thank exist
partnership croma stada await synergi across bain
capit healthcar portfolio call option
linger concern
china despit
valuat recent bottom compar peer initi
outperform rate target price base mix
dcf price-to-earnings methodolog believ recent valuat derat
seem overdon near-term growth immin thank on-going
botulinum toxin export anticip dermal filler market submiss
china pmi normalis impli price-to-earnings
recur busi stand histor lower-end averag
standard deviat offer favour entri point
valuat metric
chg prev ep
price rel chart measur perform
kosdaq se kosdaq min inx close
spot exchang rate
good sold
profit tax
free cash flow firm
net chang cash
hugel inc biopharmaceut compani focus
product includ botulinum toxin filler
bull case tp deriv mix dcf
price-to-earnings valuat factor approv chanc
china product launch toxin/fil also botulinum toxin
product approv us/eu also appli higher price-to-earnings
multpl averag standard deviat histor valuat
bear case tp deriv mix dcf
price-to-earnings valuat factor approv chanc
china product launch toxin/fil also botulinum toxin
product approv us/eu also appli lower price-to-earnings
multpl averag standard deviat histor valuat
price rel chart measur perform kosdaq se
kosdaq min inx close
spot exchang rate
figur hugelexport destin
compani mention price
